Efgartigimod in refractory autoimmune myasthenia gravis [PDF]
Muscle and NerveIntroduction/AimsEfgartigimod, a neonatal Fc-receptor inhibitor, has recently been approved as treatment for myasthenia gravis (MG). In this retrospective cohort study, we aimed to systematically assess short- and long-term effectiveness of efgartigimod ...
Linda Remijn-Nelissen +2 more
exaly +6 more sources
Annals of Clinical and Translational NeurologyBackground Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG).
Lei Jin +11 more
doaj +2 more sources
Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series [PDF]
Frontiers in ImmunologyThe coexistence of myasthenia gravis (MG) with other IgG-mediated autoimmune diseases represents a clinically heterogeneous condition, driven by pathogenic autoantibodies.
Yunjia Li +11 more
doaj +2 more sources
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus [PDF]
Frontiers in Immunology, 2022 BackgroundImmunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus are debilitating autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal ...
Maud Maho-Vaillant +13 more
doaj +3 more sources
Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients [PDF]
Frontiers in NeurologyBackgroundEfgartigimod was approved in Japan in January 2022 for the treatment of generalized myasthenia gravis (gMG), regardless of antibody status. This case series describes a real-world experience in Japan of efgartigimod treatment for gMG patients ...
Toshiya Nomura +4 more
doaj +3 more sources
Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA [PDF]
Neurology and TherapyIntroduction Oral corticosteroids (OCSs) and nonsteroidal immunosuppressant therapies (NSISTs) remain widely used for the clinical management of patients with generalized myasthenia gravis (gMG), despite well-documented risks.
Francesco Saccà +4 more
doaj +2 more sources
Efgartigimod for Guillain–Barré syndrome: a retrospective analysis of efficacy and safety [PDF]
Therapeutic Advances in Neurological DisordersBackground: Guillain–Barré syndrome (GBS) is an acute autoimmune neuropathy with limited effective treatments. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, may offer a novel treatment by reducing pathogenic immunoglobulin G.
Zhuajin Bi +5 more
doaj +2 more sources
Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain–Barré syndrome [PDF]
Orphanet Journal of Rare DiseasesObjective This study aimed to compare the effectiveness of intravenous efgartigimod and intravenous immunoglobulin (IVIg) in patients with Guillain–Barré syndrome (GBS).
Huiqiu Zhang +10 more
doaj +2 more sources
Efgartigimod in the treatment of Guillain-Barré syndrome: case report
Frontiers in ImmunologyGuillain–Barré syndrome (GBS) is a rare neurological disorder characterized by muscle weakness and paralysis. Although the exact etiology remains unclear, the current standard treatments include intravenous immunoglobulin (IVIG) and plasma exchange (PLEX)
Min Deng +4 more
doaj +3 more sources
Case Report: A Patient with Lambert-Eaton Myasthenic Syndrome Successfully Treated with Efgartigimod [PDF]
International Medical Case Reports JournalLizhu Han,1,2 Jili Shen,3 Jie Wei,3 Yue Zhang2 1Department of Neurology, Anhui No.2 Provincial People’s Hospital, Hefei, Anhui, People’s Republic of China; 2Department of Neurology, National Center for Neurological Disorders, Huashan Rare Disease Centre,
Han L, Shen J, Wei J, Zhang Y
doaj +2 more sources